The Pharmaceutical industry has seen a decline in M&A deals that have taken place in the last few years. Figure 1 shows the decrease in the number of M&A deals in Oncology over the last two years of 26% from 2016 to 2017 however the average deal value showed a more significant drop of 32%.
Figure 2 also shows the decline of Oncology Licensing Agreement Deals over the last 5 years. This shows the pressures that the Pharmaceutical industry sector face and for 2018 managing costs and pricing will be a great challenge. The biotech industry still remain lucrative these trends prove that companies will still need to re-look at efforts to streamline and improve efficiencies for the future as well as mitigating risks.